CEOs and Contract Manufacturers
Targeted in Latest Warning Letters

FDA sent six of its last nine drug GMP warning letters to contract manufacturing facilities. Most of the letters emphasized corporate accountability, and many went directly to CEOs.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet